Business
One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial
One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\n\n BATON ROUGE, La., Dec. 21, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (\"OncBioMune\" or the \"Company\"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology, targeted cancer therapies and commercialization of a portfolio of products internationally, is pleased to provide one-year follow-up results from the Company’s Phase 1 clinical trial of ProscaVax for prostate cancer.\n In the trial, hormone-naïve and hormone-independent recurrent prostate cancer patients with increasing prostate specific antigen (PSA) were treated with six intradermal injections of ProscaVax. ProscaVax is OncBioMune's novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).  The latest data shows: Progression-Free Survival 71.4%:  10 of 14 patients (71.4%), who have been followed for one year after initiation of ProscaVax therapy, continue to have stable disease Overall Survival 100%:  None of the 14 evaluable patients have died at one-year follow-upAs previously disclosed, four patients had disease progression within 19 weeks (3 PSA progression and 1 radiological progression).  No further progression has been noted from week 19 to one yearData continues to confirm there were no drug-related serious adverse events or dose-limiting toxicities resulting from ProscaVax therapySix of the 20 patients enrolled in the trial have not yet been followed for one year, evaluations to follow “I continue to be impressed with the clinical results on ProscaVax. These results support the benefit of this first-in-class immunotherapy and offers hope to cancer patients in great need,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “These are men who have tried conventional treatments only to have their cancer return and where ProscaVax now seems to be delivering a therapeutic benefit. While Progression-Free Survival and Overall Survival are benchmarks of later-stage studies and not the primary endpoints in our Phase 1 clinical trial, it is hard to overlook the finding that patients with progressing disease now have stable disease following Prosca...